Biohaven [BHVN] vs Amylyx [AMLX] Detailed Stock Comparison

Biohaven Ltd.

NYSE
Loading...

Amylyx Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 15 vital metrics comparison: Biohaven Ltd. wins in 1 metrics, Amylyx Pharmaceuticals Inc. wins in 11 metrics, with 2 ties. Amylyx Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Biohaven Ltd. Amylyx Pharmaceuticals Inc. Better
P/E Ratio (TTM) N/A 2.54 N/A
Price-to-Book Ratio 26.84 6.31 Amylyx Pharmaceuticals Inc.
Debt-to-Equity Ratio 546.58 1.95 Amylyx Pharmaceuticals Inc.
PEG Ratio -5.26 -0.06 Amylyx Pharmaceuticals Inc.
EV/EBITDA -2.22 -10.64 Biohaven Ltd.
Profit Margin (TTM) 0.00% 0.00% Tie
Operating Margin (TTM) 0.00% 0.00% Tie
Return on Equity -310.75% -61.59% Amylyx Pharmaceuticals Inc.
Return on Assets (TTM) -83.02% -36.41% Amylyx Pharmaceuticals Inc.
Free Cash Flow (TTM) $-610.15M $-123.48M Amylyx Pharmaceuticals Inc.
1-Year Return -27.04% 164.31% Amylyx Pharmaceuticals Inc.
Enterprise Value $1.55B $1.63B Amylyx Pharmaceuticals Inc.
Earnings per Share (Diluted) $-6.86 $-1.53 Amylyx Pharmaceuticals Inc.
Beta (Stock Volatility) 3.62 -0.21 Amylyx Pharmaceuticals Inc.
Short % of Float 20.25% 13.92% Amylyx Pharmaceuticals Inc.

Biohaven Ltd. vs Amylyx Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

BHVN
AMLX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biohaven Ltd.7.62%9.17%38.58%25.93%7.62%11.99%
Amylyx Pharmaceuticals Inc.4.11%16.76%14.38%5.63%20.94%33.01%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biohaven Ltd.-27.04%-52.30%54.52%-37.02%-37.02%-37.02%
Amylyx Pharmaceuticals Inc.164.31%-38.88%-19.26%-19.26%-19.26%-19.26%

Performance & Financial Health Analysis: Biohaven Ltd. vs Amylyx Pharmaceuticals Inc.

MetricBHVNAMLX
Market Information
Market Cap i$1.49B$1.91B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,841,6351,099,346
90 Day Avg. Volume i2,141,9921,107,595
Last Close$12.14$15.19
52 Week Range$7.48 - $18.57$4.80 - $18.60
% from 52W High-34.61%-18.36%
All-Time High$67.86 (Jun 03, 2019)$41.93 (Jan 30, 2023)
% from All-Time High-82.11%-63.77%
Growth Metrics
Quarterly Revenue GrowthN/AN/A
Quarterly Earnings GrowthN/AN/A
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i0.00%0.00%
Return on Equity (TTM) i-3.11%-0.62%
Debt to Equity (MRQ) i546.581.95
Cash & Liquidity
Book Value per Share (MRQ)$0.39$2.78
Cash per Share (MRQ)$2.12$2.87
Operating Cash Flow (TTM) i$-609,438,016$-123,343,000
Levered Free Cash Flow (TTM) i$-358,118,432$-66,994,876
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Biohaven Ltd. vs Amylyx Pharmaceuticals Inc.

MetricBHVN (Apr 26, 2026)AMLX (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A2.54
Forward P/E i-5.26-14.30
PEG Ratio i-5.26-0.06
Price to Sales (TTM) iN/AN/A
Price to Book (MRQ) i26.846.31
Market Capitalization
Market Capitalization i$1.49B$1.91B
Enterprise Value i$1.55B$1.63B
Enterprise Value Metrics
Enterprise to Revenue iN/AN/A
Enterprise to EBITDA i-2.22-10.64
Risk & Other Metrics
Beta i3.62-0.21
Book Value per Share (MRQ) i$0.39$2.78

Financial Statements Comparison: Biohaven Ltd. vs Amylyx Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBHVN (2025)AMLX (2025)
Revenue/Sales i00
Cost of Goods Sold iN/A0
COGS % of Revenue i--
Gross Profit iN/A0
Gross Margin i--
Research & Development i635.07M90.40M
Operating Income (EBIT) i-745.38M-153.29M
Operating Margin i--
EBITDA i-735.46M-152.77M
EBITDA Margin i--
Pre-Tax Income i-737.38M-144.69M
Pre-Tax Income % of Revenue i--
Income Tax i1.44M46,000
Income Tax % of Revenue i--
Net Income (Profit) i-738.82M-144.74M
Profit Margin i--

Balance Sheet & Liquidity Metrics

MetricBHVN (2025)AMLX (2025)
Cash & Equivalents i229.96M226.65M
Total Current Assets i368.33M323.67M
Total Current Assets % of Revenue i--
Total Current Liabilities i115.93M22.69M
Total Current Liabilities % of Revenue i--
Long-Term Debt i278.86M4.70M
Long-Term Debt % of Revenue i--
Total Shareholders Equity i52.07M305.26M
Retained Earnings i-2.08B-751.43M
Retained Earnings % of Revenue i--
Property, Plant & Equipment i45.06M5.18M

Cash Flow Statement Comparison

MetricBHVN (2025)AMLX (2025)
Operating Cash Flow i-617.91M-115.20M
Operating Cash Flow % of Revenue i--
Capital Expenditures i-715,000-138,000
Free Cash Flow i-610.15M-123.48M
FCF Margin i--
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBHVNAMLX
Shares Short i23.77M14.23M
Short Ratio i9.2113.56
Short % of Float i20.25%13.92%
Shares Outstanding i132.78M109.88M
Float Shares i123.86M82.88M
% Held by Insiders i11.09%7.95%
% Held by Institutions i91.64%104.29%
% Held by Public i-2.73%-12.24%

Dividend Analysis & Yield Comparison: Biohaven Ltd. vs Amylyx Pharmaceuticals Inc.

MetricBHVNAMLX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A